Intelligence · Clinical Development
Pipeline search results
Programs matching “air” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 160 pipeline programs matching "air" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
MCI-186
Tanabe Pharma
Renal Impairment
1 trial -
MGL-3196
Madrigal Pharmaceuticals EU Limited
Hepatic Impairment
1 trial -
Medium THC
BRIGHT MINDS BIOSCIENCES INC.
Marijuana Impairment
1 trial -
Mitapivat
Agios Netherlands B.V.
Moderate Hepatic Impairment
1 trial -
Mobocertinib
Takeda
Hepatic Impairment
1 trial -
Mobocertinib
Takeda
Renal Impairment
1 trial -
NBI-98854 50 mg capsule
NEUROCRINE BIOSCIENCES INC
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
1 trial -
NN9490-8156
NovoThirteen
hepatic impairment
1 trial -
Nalbuphine ER
Trevi Therapeutics
Hepatic Impairment
1 trial -
PH-L19IL2CORK-01/25
Philogen S.p.A.
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
Relacorilant
CORCEPT THERAPEUTICS INC
Hepatic Impairment
1 trial -
SPR206
Spero Therapeutics
Renal Impairment
1 trial -
SSP-004184
Takeda
Impaired Renal Function
1 trial -
SSP-004184
Takeda
Hepatic Impairment
1 trial -
STP237
Biocodex
Patients with renal impairement
1 trial -
Sativex
Jazz Pharmaceuticals Ireland Limited
Hepatic Impairment
1 trial -
Sotagliflozin
LEXICON PHARMACEUTICALS, INC.
Renal Impairment
1 trial -
Soticlestat
Takeda
Hepatic Impairment
1 trial -
TAK-272
Takeda
Renal Impairment
1 trial -
TAK-279
Takeda
Renal Impairment
1 trial -
TAK-279
Takeda
Hepatic Impairment
1 trial -
TAK-954
Takeda
Renal Impairment
1 trial -
TAK-954
Takeda
Hepatic Impairment
1 trial -
TD-4208
Theravance Biopharma Ireland Umited
Hepatic Impairment
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.